IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma

Biochemical and Biophysical Research Communications

Volumn 407, Issue 2, 2011, Pages 348-354

  Liu, Jiankun ^a   Duan, Yuzhong ^a   Cheng, Xiaoming ^a   Chen, Xi ^a   Xie, Wei ^a   Long, Haixia ^a   Lin, Zhihua ^b   Zhu, Bo ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHONGQING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Colorectal carcinoma; IL 17; Prognosis; VEGF

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 17; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; COLORECTAL CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TH17 CELL; TUMOR IMMUNOLOGY; TUMOR VASCULARIZATION;

ADULT; ANTIGENS, CD; ANTIGENS, CD5; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CARCINOMA; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 79953681584     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.03.021     Document Type: Article

References (26)

1. Folkman J. Angiogenesis in cancer, vascular rheumatoid and other disease. Nat. Med. 1995, 1:27-31.
2. McCarthy M. Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet 2003, 361:1959.
3. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
4. Danese S., Mantovani A. Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene 2010, 29:3313-3323.
5. Wójcik E., Jakubowicz J., Skotnicki P., Sas-Korczyńska B., Kulpa J.K. IL-6 and VEGF in small cell lung cancer patients. Anticancer Res. 2010, 30:1773-1778.
6. Meng Y., Beckett M.A., Liang H., et al. Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res. 2010, 70:1534-1543.
7. Weaver C.T., Hatton R.D., Mangan P.R., Harrington L.E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 2007, 25:821-852.
8. Dong C.T.H. 17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol. 2008, 8:337-348.
9. Steiner G.E., Newman M.E., Paikl D., et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003, 56:171-182.
10. Chen X., Wan J., Liu J., et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 2010, 69:348-354.
11. Zhang J.P., Yan J., Xu J., et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol. 2009, 50:980-989.
12. Zhu X., Mulcahy L.A., Mohammed R.A., et al. IL-17 expression by breast-cancer-associated macrophages. IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res. 2008, 10:R95.
13. Miyahara Y., Odunsi K., Chen W., Peng G., Matsuzaki J., Wang R.F. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc. Natl. Acad. Sci. USA 2008, 105:15505-15510.
14. Le Gouvello S., Bastuji-Garin S., Aloulou N., et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008, 57:772-779.
15. Murugaiyan G., Saha B.P. Rotumor vs. antitumor functions of IL-17. J. Immunol. 2009, 183:4169-4175.
16. Numasaki M., Fukushi J., Ono M., et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003, 101:2620-2627.
17. Kato T., Furumoto H., Ogura T., et al. Expression of IL-17 mRNA in ovarian cancer. Biochem. Biophys. Res. Commun. 2001, 282:735-738.
18. Numasaki M., Watanabe M., Suzuki T., et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J. Immunol. 2005, 175:6177-6189.
19. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin. Diagn. Pathol. 1993, 10:302-313.
20. Shibusa T., Shijubo N., Abe S. Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin. Cancer Res. 1998, 4:1483-1487.
21. Numasaki M., Lotze M.T., Sasaki H. Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol. Lett. 2004, 93:39-43.
22. Takahashi H., Numasaki M., Lotze M.T., Sasaki H. Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol. Lett. 2005, 98:189-193.
23. Calviello G., Di Nicuolo F., Gragnoli S. n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway. Carcinogenesis 2004, 25:2303-2310.
24. Chung Y.C., Chang Y.F. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J. Surg. Oncol. 2003, 83:222-226.
25. Nakasaki T., Wada H., Shigemori C., et al. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am. J. Hematol. 2002, 69:247-254.
26. Kuang D.M., Peng C., Zhao Q., Wu Y., Chen M.S., Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 2010, 51:154-164.